RSCM
Rock Springs Capital Management Portfolio holdings
AUM
$1.6B
This Quarter Return
-6.58%
1 Year Return
+25.98%
3 Year Return
+194.74%
5 Year Return
+336.76%
10 Year Return
+2,199.29%
AUM
$3.73B
AUM Growth
+$3.73B
(-11%)
Cap. Flow
-$74.6M
Cap. Flow
% of AUM
-2%
Top 10 Holdings %
Top 10 Hldgs %
36%
Holding
129
New
6
Increased
41
Reduced
24
Closed
9
Top Buys
| 1 |
Boston Scientific
BSX
|
$47.1M |
| 2 |
Penumbra
PEN
|
$33.3M |
| 3 |
BPMC
Blueprint Medicines
BPMC
|
$25M |
| 4 |
Immunovant
IMVT
|
$24.7M |
| 5 |
Amgen
AMGN
|
$18.3M |
Top Sells
| 1 |
argenx
ARGX
|
$44.7M |
| 2 |
Spyre Therapeutics
SYRE
|
$40.1M |
| 3 |
Insulet
PODD
|
$28.5M |
| 4 |
CONMED
CNMD
|
$27.9M |
| 5 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$27.7M |
Sector Composition
| 1 | Healthcare | 97.08% |
| 2 | Consumer Staples | 1.17% |
| 3 | Industrials | 0.83% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Humana
HUM
$36.5B
| $212M | 5.69% | 436,500 -33,500 | -7% | -$16.3M |
|
2
Immunocore
IMCR
$1.62B
| $153M | 4.09% | 2,943,710 -84,700 | -3% | -$4.4M |
|
3
Agilon Health
AGL
$530M
| $147M | 3.95% | 8,292,500 +10,000 | +0.1% | +$178K |
|
4
Neurocrine Biosciences
NBIX
$13.8B
| $139M | 3.72% | 1,236,000 -43,500 | -3% | -$4.89M |
|
|
BPMC
5
DELISTED
Blueprint Medicines
BPMC
| $135M | 3.61% | 2,685,294 +498,622 | +23% | +$25M |
|
|
6
argenx
ARGX
$43.6B
| $127M | 3.41% | 259,000 -91,000 | -26% | -$44.7M |
|
|
7
Penumbra
PEN
$10.6B
| $122M | 3.26% | 503,750 +137,750 | +38% | +$33.3M |
|
8
UnitedHealth
UNH
$281B
| $116M | 3.11% | 230,000 | – | – |
|
9
Evolent Health
EVH
$1.12B
| $105M | 2.82% | 3,865,000 +61,500 | +2% | +$1.67M |
|
10
Intuitive Surgical
ISRG
$170B
| $87.2M | 2.34% | 298,500 | – | – |
|
|
KRTX
11
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $85.5M | 2.29% | 505,433 +11,906 | +2% | +$2.01M |
|
12
Idexx Laboratories
IDXX
$51.8B
| $85M | 2.28% | 194,500 | – | – |
|
|
SGEN
13
DELISTED
Seagen Inc. Common Stock
SGEN
| $84.9M | 2.27% | 400,200 | – | – |
|
14
West Pharmaceutical
WST
$17.8B
| $75.8M | 2.03% | 202,000 | – | – |
|
15
Akero Therapeutics
AKRO
$3.74B
| $71.8M | 1.92% | 1,419,150 -131,604 | -8% | -$6.66M |
|
16
Exact Sciences
EXAS
$8.98B
| $69.5M | 1.86% | 1,018,250 +74,750 | +8% | +$5.1M |
|
17
Agios Pharmaceuticals
AGIO
$2.19B
| $67.1M | 1.8% | 2,710,061 +23,894 | +0.9% | +$591K |
|
18
Align Technology
ALGN
$10.3B
| $66.3M | 1.77% | 217,000 | – | – |
|
19
Acadia Healthcare
ACHC
$2.12B
| $63.8M | 1.71% | 908,000 | – | – |
|
|
20
Boston Scientific
BSX
$156B
| $61.2M | 1.64% | 1,160,000 +892,500 | +334% | +$47.1M |
|
|
21
Insulet
PODD
$23.9B
| $60.6M | 1.62% | 380,000 -179,000 | -32% | -$28.5M |
|
22
Mirum Pharmaceuticals
MIRM
$3.71B
| $57.5M | 1.54% | 1,820,733 | – | – |
|
|
CERE
23
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $55.2M | 1.48% | 2,529,116 +15,200 | +0.6% | +$332K |
|
24
DexCom
DXCM
$29.5B
| $54.5M | 1.46% | 584,000 +93,500 | +19% | +$8.72M |
|
25
Ultragenyx Pharmaceutical
RARE
$2.89B
| $52.6M | 1.41% | 1,476,441 +92,172 | +7% | +$3.29M |
|